PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock

Delisted

PHAS was delisted on the 2nd of November, 2022.

38 hedge funds and large institutions have $3.89M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 12 closing their positions.

Holders
38
Holders Change
-11
Holders Change %
-22.45%
% of All Funds
0.66%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
6
Reduced
12
Closed
12
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Shares
Change %
HI
26
Harbour Investments
Wisconsin
$2K
Osaic Holdings
27
Osaic Holdings
Arizona
$1K
TWC
28
TD Waterhouse Canada
Ontario, Canada
$211
BNP Paribas Financial Markets
29
BNP Paribas Financial Markets
France
$14
CA
30
CHI Advisors
New York
-$450K -750,000 Closed
NLG
31
New Legacy Group
New York
-$144K -240,575 Closed
Marshall Wace
32
Marshall Wace
United Kingdom
-$73K -123,039 Closed
Citadel Advisors
33
Citadel Advisors
Florida
-$65K -107,953 Closed
Prudential Financial
34
Prudential Financial
New Jersey
-$26K -44,100 Closed
VF
35
Virtu Financial
New York
-$19K -31,852 Closed
Millennium Management
36
Millennium Management
New York
-$8K -13,501 Closed
TSS
37
Two Sigma Securities
New York
-$8K -12,845 Closed
Two Sigma Advisers
38
Two Sigma Advisers
New York
-$8K -12,700 Closed
UBS Group
39
UBS Group
Switzerland
-$6K -9,830 Closed
Toronto Dominion Bank
40
Toronto Dominion Bank
Ontario, Canada
-$3K -4,670 Closed